AzTrials
AzTrials

Plantar WartEarly Phase 1NCT04823845

Plantar Wart Treatment Using Adapalene Gel

A Early Phase 1 study testing Topical Adapalene Gel 0.1% in people with Plantar Wart, run by University of Louisville.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study seeks to research the efficacy of Adapalene 0.1% gel as a cost effective and low risk treatment option for plantar warts of the foot. Patients that present/diagnosed in designated clinics with plantar warts will be offered the option of being treated with regular superficial debridements of the epidermis… Read more about this study

Who is it for?
Ages 6 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Plantar Wart
What is being tested?
Topical Adapalene Gel 0.1%
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
1 May 2022to 10 Feb 2023
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • patients must be diagnosed with plantar warts

Who cannot join

  • pregnant women
  • previous wart treatment within the last 2 weeks

About this study

This study seeks to research the efficacy of Adapalene 0.1% gel as a cost effective and low risk treatment option for plantar warts of the foot. Patients that present/diagnosed in designated clinics with plantar warts will be offered the option of being treated with regular superficial debridements of the epidermis and twice a day application of adapalene gel 0.1% under occlusion. Patients will be followed until resolution.

Read the detailed description

PROBLEM/BACKGROUND: Plantar warts are the result of a DNA virus called Human Papilloma Virus (HPV), specifically subtypes 1,2,4,27, and 57. Plantar warts are a common complaint among adults and children when standing, walking or running as they are on the weight-bearing surface of the foot. These cutaneous infections often occur when walking barefoot at public pools, sidewalks, bathhouses etc. and the epidermis becomes compromised. Surfaces carrying HPV is transmitted and infects the keratinocyte in the compromised skin and begins hyperplasia in the granular, prickle layers, and the dermal papillae. Histologically cell nuclei are eccentrically seen surrounded by koilocytes (halos). This manifests as a hyperkeratotic cutaneous lesion that is a dermal outpouching with break in normal skin lines, painful with lateral or direct pressure, and pin point bleeding. These lesions are often self limiting and resolve in time. However, patients often complain of pain and seek treatments.

Patients often try over the counter remedies with no avail, and then seek professional help for the issue. The standard of care for clinicians is often to use debridement with some form of keratolytic topical agent, such as: salicylic acid, canthridin is used; or cryotherapy, laser (pulse dye or CO2), bleomycin or candida injections are commonly used. Surgical excision is often utilized as well. These treatments are often invasive, painful, and require multiple sessions over a long period of time. Research has suggested the use of adapalene gel 0.1% as a less invasive and faster therapy for plantar warts. The purpose of this study is to test a United States population with Adapalene Gel 0.1% for plantar warts as a viable treatment option with the goals of being faster and less invasive.

OBJECTIVES: Test United States population in the treatment of plantar warts using adapalene gel 0.1%. Measure the amount of time until resolution of the plantar wart using this treatment. Document patient pain with this treatment method.

STUDY DESIGN: Clinician Interventional Prospective Study. Goal of minimum 50 patients will be studied from ages 5-90 years old of all health statuses, race, and genders. Pregnant women will be excluded due to very minimal, but medicine recommendations and guidelines. Patients presenting to outpatient clinics with plantar warts will be treated with a debridement with scalpel down to dermis followed by application of Adapalene 0.1% gel under occlusion. Patients will apply this twice a day under occlusion and return for repeat debridements every 2 weeks. Warts will be measured initially and before and after each debridement until resolution. Patient pain will be assessed each visit and documented.

SUBJECT RECRUITMENT: Patients will present to outpatient clinics, and if diagnosed with a plantar wart will be offered the standard of care treatment at that clinic or the Adapalene gel study treatment if they have not tried any other therapies for 2 weeks. Patients will have the option for the standard of care at the clinic or choose the treatment option of this study. Pregnant women will be excluded. Any patient having received another treatment therapy in the last 2 weeks will be excluded.

INFORMED CONSENT: Patients included in the study will be informed that this is not the standard of care, and that the standard of care is actually more invasive. This alternative treatment has been researched and has evidence to be safer, less invasive, and faster than the current standard of care. Patients will have the option to choose.

RESEARCH PROCEDURES: The research group will have their plantar warts photographed, pain assessed, measured, debrided down to the dermal layer using a sterile 15 scalpel, re-measured, apply adaplene 0.1% gel to area, cover with occlusive bandage. Patient will apply this adapelene gel 0.1% twice a day daily and keep covered at all times.

STATISTICAL ANALYSIS: Descriptive and inferential statistics will be calculated on 50 patients recruited into the study who had plantar warts. Measures taken will be the age and sex of patients, duration of warts in months, size of warts, time taken to remove the warts by using Adapalene gel 0.1% under occlusion, and side effects of usage such as irritation, erethyma, and scar tissue. Statistics will include frequency and percentages, and means ± standard deviations where appropriate. Confidence intervals (95 CIs) will be calculated around the time taken to remove the warts. A sample size and power analysis showed that if the mean time to remove the warts using Adapalene gel was 37 days with a standard deviation of 19, a sample size of 50 would allow us to obtain 95% CIs of 31.6, 42.4 days." RESEARCH MATERIALS: Patient's age, gender, race, BMI will be recorded in the EMR as well as wart size, photo, and pain level each visit.

Conditions
Plantar Wart
Being tested
Topical Adapalene Gel 0.1%
Keywords
Wart, Adapalene
Medical subject headings
Warts

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Topical Adapalene Gel 0.1%Drug

    applying Adapalene Gel 0.1% to plantar warts topically

Study groups in NCT04823845
Study groupRoleWhat they receive
Plantar Wart Treatment Using Adapalene Gel 0.1%Experimentalpatients treated for plantar warts with Adapalene 0.1% gel
Receives: Drug: Topical Adapalene Gel 0.1%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time Until Plantar Wart Resolution

    days

    Measured: 30-60 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2021
  2. Study start1 May 2022 (estimated)
  3. Primary completion10 Dec 2022 (estimated)
  4. Study completion10 Feb 2023 (estimated)

Why it stopped: Study never received IRB approval.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
apply study treatment to single group of patients.
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04823845
Sponsor's protocol ID
20.1175
Status last verified
Apr 2023
First submitted
5 Mar 2021
Last updated
13 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: IPD will only be obtained/used by the researchers and no individual patient identifiers will be used.

Publications

  • Gupta R, Gupta S. Topical adapalene in the treatment of plantar warts; randomized comparative open trial in comparison with cryo-therapy. Indian J Dermatol. 2015 Jan-Feb;60(1):102. doi: 10.4103/0019-5154.147835.

    PubMed 25657417
  • Gupta R. Plantar warts treated with topical adapalene. Indian J Dermatol. 2011 Sep-Oct;56(5):513-4. doi: 10.4103/0019-5154.87135.

    PubMed 22121266
  • Vlahovic TC, Khan MT. The Human Papillomavirus and Its Role in Plantar Warts: A Comprehensive Review of Diagnosis and Management. Clin Podiatr Med Surg. 2016 Jul;33(3):337-53. doi: 10.1016/j.cpm.2016.02.003. Epub 2016 Mar 29.

    PubMed 27215155

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Topical Adapalene Gel 0.1% in people with Plantar Wart, run by University of Louisville.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 13 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time Until Plantar Wart Resolution (time frame: 30-60 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04823845, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in